TABLE 2.
Amino acid substitutions identified in the RSV G and F proteins of RSV-A
| G gene | F gene | ||||
|---|---|---|---|---|---|
| Antigenic site/structural domain | Amino acid substitutions | Frequency (%) | Antigenic site/structural domain | Amino acid substitutions | Frequency (%) |
| Cytoplasmic 1–37 |
–a | – | Ø 62–96 195–227 (nirsevimab) |
– | – |
| Transmembrane domain 38–66 |
A57T | 11.04 | I 27–45 312–318 378–389 |
– | – |
| First hypervariable region 67–160 |
P71L H90Y S100N L101F G106E P120L S121I I134K T137K L142S P143S |
99.69 99.37 11.08 98.75 71.34 68.89 68.89 100.00 11.64 84.76 68.79 |
II 254–277 (palivizumab) |
K272N S276N |
4.44 2.20 |
| Conserved domain 161–200 |
– | – | III 46–54 301–311 345–352 367–378 |
S377N | 2.52 |
| Second hypervariable region 192–322 |
P217S G224E G224V P230H N242T S243I K262E I265L D284G S294P G296S S299N Y304H T319A T319I T320A |
68.47 88.92 11.08 10.69 68.79 99.37 99.37 99.68 100.00 11.08 68.79 69.52 94.30 69.45 19.94 91.43 |
IV 422–471 |
– | – |
| V 55–61 146–194 287–300 |
I59V | 7.23 | |||
| SP 1–25 |
A10T T12I T13A C21W |
7.23 5.99 1.89 2.52 |
|||
| p27 109–136 |
T122A N124T V127I |
8.81 7.23 11.04 |
|||
| TM 530–549 |
– | – | |||
| Undefined sites | S99N A103T |
11.67 8.81 |
|||
a
“–” indicates that no amino acid changes were identified.